Ethylene

Ethylene

SCHEMBL3968587

C=C.N#CC1(c2ccccc2F)CCC(=O)CC1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
CYP2C9 P11712 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC4 P56524 2/20 0.36
BDKRB1 P46663 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1557008 0.97 MEN1 (0.39) MEN1CYP2C9KMT2AALDH1A1NPC1
SCHEMBL1769351 0.82 HDAC4 (0.41) ALDH1A1NPC1LMNATP53NFKB1
SCHEMBL30929543 0.82 HDAC4 (0.41) ALDH1A1NPC1LMNATP53NFKB1
SCHEMBL4431082 0.79 PSEN1 (0.49) KMT2APDE4APDE4BPDE4CPDE4D
SCHEMBL1020368 0.79 NPC1 (0.48) MEN1KMT2AALDH1A1NPC1LMNA
SCHEMBL625354 0.79 NPC1 (0.44) MEN1KMT2AALDH1A1NPC1LMNA
SCHEMBL2289999 0.79 MEN1 (0.38) MEN1CYP2C9KMT2AALDH1A1PDE4A
SCHEMBL2288498 0.79 ADRA1A (0.42) MEN1CYP2C9KMT2ALMNAHDAC4
SCHEMBL7949441 0.79 MEN1 (0.38) MEN1CYP2C9KMT2APDE4APDE4B
SCHEMBL3159094 0.79 MEN1 (0.38) MEN1CYP2C9KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772296-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-07-08 US disclosed
EP-2044004-A2 BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY Amgen Inc. (US) 2009-04-08 EP disclosed
US-20070299080-A1 N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy AMGEN INC. 2007-12-27 US disclosed
WO-2007145835-A2 BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY AMGEN INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299080-A1 N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy HSD3B1, HSD17B1, HSD3B2 MEN1 1920/4885CYP2C9 785/4885KMT2A 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.